RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM

• US 20110195116A1
• Filed: 08/18/2009
• Published: 08/11/2011
• Est. Priority Date: 08/19/2008
• Status: Abandoned Application

• Current Assignee: Adcock Ingram Healthcare Limited (Bidvest Group Limited)
• Original Assignee: Adcock Ingram Healthcare Limited (Bidvest Group Limited)
• Inventors: Pillay, Viness, Hobbs, Kim Melissa, Choonara, Yahya Essop, Parsons, Bradley Ryan
• Application Number:
  US13/059,803
• Publication Number:
  US 20110195116A1
• Time in Patent Office: Days
• US Class Current: 424/451
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2072 characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/0004, A61K9/0056, A61K9/0065 take precedence
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastrointestinal tract, in a predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet preferably three layers and each layer includes an API or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location. Methods of manufacturing said dosage form are further disclosed.

Claims

1. A pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body in a predetermined rate-modulated manner.

2. A pharmaceutical dosage form as claimed in claim 1 in which the desired absorption location of the human or animal body is the gastrointestinal tract.

3. A pharmaceutical dosage form as claimed in claim 1 in which the dosage form is orally ingestible.

4. A pharmaceutical dosage form as claimed in claim 3 in which the dosage form is in the form of a tablet or capsule.

5. A pharmaceutical dosage form as claimed claim 1 in which the dosage form is in the form of a multilayered tablet and each layer to includes an API, or the pharmaceutically active salts and isomers thereof.

6. A pharmaceutical dosage form as claimed in claim 5 in which the APIs are tramadol, paracetamol and diclophenac, each of which is deliverable to a desired absorption location of the gastrointestinal tract.

7. A pharmaceutical dosage form as claimed in claim 1 in which the dosage form is in the form of a capsule and for the API or APIs or the pharmaceutically active salts and isomers thereof, are formed into discrete granules which are located within the capsule.

8. A pharmaceutical dosage form as claimed in claim 7 in which the APIs are tramadol, paracetamol and diclophenac,

9. A pharmaceutical dosage form as claimed claim 1 in which the or each API is integrated into a platform formed from at least one polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location.

10. A pharmaceutical dosage form as claimed in claim 1 in which the or each API, or the pharmaceutically active salts and isomers thereof, is or are mixed with one or more excipients having a known chemical interaction including crosslinking, dissolution rate of pH dependency, erodibility and/or swellability so that, in use, the or each API, or the pharmaceutically active salts and isomers thereof, can be released over a desired period of time.

11. A pharmaceutical dosage form as claimed in claim 9 in which the polymer or polymers used in the pharmaceutical dosage form is or are one or more of:

a standard hydrophilic polymer or polymers, a hydrophilic swellable and/or erodible polymer or polymers, a standard hydrophobic polymer or polymers, a hydrophobic swellable and/or erodible polymer or polymers.

12. A pharmaceutical dosage form as claimed in claim 11 in which the polymer or polymers is or are selected from the group consisting of:

hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), polyethylene oxide (PEO), polyvinyl alcohol (PVA), sodium alginate, pectin, ethylcellulose (EC), poly(lactic) co-glycolic acids (PLGA), polylactic acids (PLA), polymethacrylates, polycaprolactones, polyesters and polyamides.

13. A pharmaceutical dosage form as claimed in claim 11 in which, the polymer or polymers is or are mixed with a co-polymer or used alone in the pharmaceutical dosage form.

14. A pharmaceutical dosage form as claimed in claim 1 in which the polymer or polymers to impart, to the API, or the pharmaceutically active salts and isomers thereof, in use, a phasic drug release profile and thus a time-controlled release of the or each API, or the pharmaceutically active salts and isomers thereof, which is released first and which is absorbed in the operatively upper regions of the gastrointestinal tract and zero-order release kinetics for an API or the pharmaceutically active salts and isomers thereof, which is released second and which is absorbed in a lower portion of the gastrointestinal tract.

15. A pharmaceutical dosage form as claimed in claim 9 in which the polymer or polymers provide, in use, first-order release kinetics of one or more APIs or the pharmaceutically active salts and isomers thereof, from a first outer layer or a tabletised dosage form having three layers and zero-order release kinetics of an API or the pharmaceutically active salts and isomers thereof, from a second outer layer of the tabletised dosage form.

16. A pharmaceutical dosage form as claimed in claim 15 in which the polymer or polymers provide, in use, first-order release kinetics of the or each APIs from one or both outer layers of the tabletised dosage form which has three layers.

17. A pharmaceutical dosage form as claimed claim 1 in which the pharmaceutically active composition or compositions are selected from one or more analgesics, preferably paracetamol, tramadol and diclofenac.

18. A pharmaceutical dosage form as claimed in claim 17 in which the or each pharmaceutically active composition is incorporated into at least one tablet-like layer of the dosage form and is mixed with various polymeric permutations and pharmaceutical excipients that are able to control the release of the said pharmaceutically active composition or compositions.

19. A pharmaceutical dosage form as claimed in claim 18 in which the tablet-like layers of the dosage form have the same alternating polymeric permutations and pharmaceutical excipients in each layer.

20. A pharmaceutical dosage form as claimed in claim 1 in which the dosage form incorporates two or more pharmaceutically active compositions which may or may not demonstrate synergistic therapeutic activity.

21. A pharmaceutical dosage form as claimed in claim 20 in which the pharmaceutically active compositions do demonstrate a synergistic therapeutic activity.

22. A pharmaceutical dosage form as claimed in claim 21 in which the pharmaceutically active compositions are paracetamol and tramadol.

23. A pharmaceutical dosage form as claimed in claim 1 in which the dosage form to include a number of pharmaceutically active compositions which are selected to provide a treatment regimen for a specific condition or conditions.

24. A pharmaceutical dosage form as claimed in claim 23 in which the condition is a circulatory disorder and the dosage form has three layers, the first layer containing, as a pharmaceutically active composition, a cholesterol medication, the second layer containing, as a pharmaceutically active composition, an antihypertensive and the third layer containing, as a pharmaceutically active composition, a blood thinning agent.

25. A pharmaceutical dosage form as claimed in claim 24 in which each of the pharmaceutically active compounds is released, in use, with a desired release kinetic profile.

26. A method of manufacturing a pharmaceutical dosage form comprising

mixing a polymer in various concentrations, a pharmaceutical excipient and at least one API or the pharmaceutically active salts and isomers thereof, to form at least one of layer of a number of layers in the pharmaceutical dosage form,

dimensioning and configuring the or each layer so that, in use an API is released therefrom over a desired period of time as a result of variations in the polymeric materials employed, pharmaceutical excipients, chemical interactions such as crosslinking that may be in situ, and/or diffusion path-lengths created.

27. A method of manufacturing a pharmaceutical dosage form as claimed in claim 26 in which the pharmaceutical dosage form is provided with at least one outer layer and, in addition to this, a middle or inner layer of rate-modulating polymeric material and at least one crosslinking reagent, to provide, in use, zero-order release kinetics of an API or the pharmaceutically active salts and isomers thereof.

28. A method of manufacturing a pharmaceutical dosage form as claimed in claim 27 in which the outer layers of the dosage form include a rate-modulating polymeric material to provide, in use, first-order release kinetics of one or more APIs or the pharmaceutically active salts and isomers thereof.

29. A method of manufacturing a pharmaceutical dosage form as claimed in claim 28 which tabletising the dosage form.

30. A method of manufacturing a pharmaceutical dosage form as in claim 29 which includes selecting the or each polymer to be selected to provide, in use, selected delivery profiles of the or each API from each tabletised layer and phasic release from two outer tablet-like layers if the said pharmaceutical dosage form comprises a total of three layers thus providing, in use, therapeutic blood levels similar to those produced by individual multiple smaller doses.

31. A method of manufacturing a pharmaceutical dosage form as in claim 26 in which the API or APIs are a combination of analgesics and for each or a combination of at least two of the APIs are incorporated into at least one tablet-like layer that is mixed with various polymeric permutations and pharmaceutical excipients that are able to control the release of the said pharmaceutically active composition.

32. A method of manufacturing a pharmaceutical dosage form as in claim 26 in which the API or APIs are a combination of analgesics and for each or a combination of at least two of the APIs are incorporated into at least one tablet-like layer that is mixed with various polymeric permutations and have the same alternating polymeric permutations and pharmaceutical excipients in each layer.

33. A method of manufacturing a pharmaceutical dosage form as in claim 26 in which the API or APIs may or may not demonstrate synergistic therapeutic activity.